CIN : L22193DL2024PLC428183

ANONDITA MEDICARE LIMITED

AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.

Manufacturer of Condoms

November 13, 2025

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Subject: **Outcome of Board Meeting held on Thursday, November 13, 2025, at 05:00 P.M. pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

We hereby inform you that as per the requirements of Regulations 30 and 33 of the Listing Regulations, as amended, from time to time, the Board of Directors of Company, at their meeting held on Thursday, November 13, 2025, at 05:00 P.M. at the corporate office of the Company situated at D-001, Sector 80, Gautam Buddha Nagar, Noida, Uttar Pradesh-201305, had taken inter alia considered the following:

1. Approved the Unaudited Standalone and Consolidated Half yearly Financial Results for the half year ended 30th September 2025 together with the Statement of Assets and Liabilities as on date and Statement of Cash Flows for the half year ended 30th September, 2025. (Enclosed herewith as an **Annexure 1**.

2. Took note of the Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the half year ended 30th September 2025, and the same is enclosed herewith as an **Annexure 2**.

The above may also be accessed on the website of the company at the link https://anonditamedicare.com/

The Board Meeting commenced at 05:00 P.M and concluded at 06:00 P.M.

We hereby request you to take the above submission on your record.

Thanking you,

For and on behalf of
Anondita Medicare Limited

ANONDITA MEDICARE LTD.

Nutan Agrawal

Nutan Agrawal
Company Secretary and Compliance Officer
Membership No. 58113


UNIT


OFFICE


DIPPING AREA


TESTING AREA

Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001
1960, First Floor, Outram Line, Delhi - 110009
Ph. : 011-23340155, 23342776 Mob:9810247478
E-mail : jainchopra.company@gmail.com

Independent Auditor's Limited Review Report on unaudited financial results of Anondita Medicare Limited for the half year ended September 30, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015

To,
The Board of Directors of Anondita Medicare Limited

We have reviewed the accompanying statement of unaudited financial results of Anondita Medicare Limited for the half year ended September 30, 2025. This Financial statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jain Chopra & Company
Chartered Accountants
FR No. 002198N

Rajesh Kumar

Rajesh Kumar
Partner
M.No. 501860
UDIN: 25501860BMLYKU9992
Date: 13-11-2025
Place: New Delhi

JAIN CHOPRA & COMPANY
NEW DELHI
CHARTERED ACCOUNTANTS

ANONDITA MEDICARE LIMITED
(Formerly known as Anondita Healthcare)
Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183

STANDALONE BALANCE SHEET AS AT 30 SEPTEMBER, 2025

(Amount in Lakh)

Particulars	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
I. EQUITY AND LIABLITIES			
1. Shareholders' funds			
(a) Share Capital	1,808.66	886.24	1,329.36
(b) Reservs and surplus	7,963.81	1,077.21	1,430.41
(c) Money received against share warrants			
2. Share application money pending allotment			
3. Non - current liabilities			
(a) Long-term borrowings	1,307.40	1,320.65	1,190.76
(b) Deferred Tax Liability (net)	24.06	17.30	8.56
(c) Other Long term liabilities			
(d) Long Term Provision	15.13	7.51	9.83
4. Current liabilities			
(a) Short-term borrowings	1,738.22	1,475.52	1,548.34
(b) Trade payables			
A) Total outstanding dues of micro enterprises and small enterprises	153.00	168.87	99.37
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	323.64	118.65	253.21
(c) Other current liabilities	265.97	123.45	134.74
(d) Short-term Provisions	732.51	79.30	361.76
Total	**14,332.39**	**5,274.70**	**6,366.35**
ASSETS			
1) Non Current Assets			
(a) Property, Plant and Equipment and Intangible assets			
(i) Property, Plant and Equipment	1,275.48	1,246.15	1,235.16
(ii) Intangible assets			
(iii) Capital Work In Progress	1,522.08	50.36	649.61
(iv) Intangible assets under development			
(b) Non-current Investments	351.58	351.58	351.58
(c) Deferred tax assets (net)			
(d) Long-term loans and advances	37.66	37.66	37.66
(e) Other non - current assets	0.20	0.30	0.24
2) Current Assets			
(a) Current investments			
(b) Inventories	1,103.36	728.35	896.28
(c) Trade receivables	3,321.36	1,405.72	1,660.42
(d) Cash and Bank balance	3,628.28	41.81	25.56
(e) Short-term loans and advances	2,360.94	1,183.80	1,173.35
(f) Other current assets	731.45	228.97	336.48
Total	**14,332.39**	**5,274.70**	**6,366.35**

For & On behalf of the Board
Anondita Medicare Limited

RESHANT GHOSH
Wholetime Director

ANONDITA MEDICARE LTD.

ANONDITA MEDICARE LIMITED
(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183

STANDALONE STATEMENT OF PROFIT & LOSS AS AT 30 SEPTEMBER, 2025

(Amount in Lakhs)

PARTICULARS	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
I. Revenue from operations	4,765.06	2,497.06	6,051.52
II. Other Income	75.56	28.65	36.38
III. Total Income (I +II)	4,840.62	2,525.70	6,087.90
IV. Expenses:			
Cost of Materials Consumed	2,353.22	1,482.69	3,376.69
Purchase of Stock-in-Trade			
Change in inventories of finished goods, Work in progress and Stock in Trade	(186.94)	3.56	(202.97)
Employee benefit expense	271.06	223.68	483.66
Financial costs	181.32	145.09	289.46
Depreciation and amortization expense	40.03	36.02	74.65
Other expenses	649.21	256.15	605.68
Total Expenses	3,307.91	2,147.20	4,627.18
V. Profit before exceptional and extraordinary items and tax (III - IV)	1,532.71	378.51	1,460.73
VI. Exceptional Items			
VII. Profit before extraordinary items and tax (V - VI)	1,532.71	378.51	1,460.73
VIII. Extraordinary Items			
IX. Profit before tax (VII - VIII)	1,532.71	378.51	1,460.73
X. Tax expense:			
(1) Current tax	370.65	78.74	361.15
(2) Deferred tax Liability / (Assets)	15.49	17.30	8.56
XI. Profit(Loss) for the year from continuing operations (IX - X)	1,146.57	282.47	1,091.01
XII. Profit/(Loss) from discontinuing operations			
XIII. Tax expense of discounting operations			
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)			
XV. Profit/(Loss) for the year (XI + XIV)	1,146.57	282.47	1,091.01
XVI. Earning per equity share:			
(1) Basic	8.14	3.05	9.70
(2) Diluted	8.14	3.05	9.70

For & On behalf of the Board
Anondita Medicare Limited

ANONDITA MEDICARE LTD.

RESHANT GHOSH
Wholetime Director

ANONDITA MEDICARE LIMITED

(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:L22193DL2024PLC428183

Standalone Statement of Cash Flow as at September 30th, 2025

(Amount In Lakhs)

Particulars	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
Profit before tax	1,532.71	378.51	1,460.73
Adjustments for:			
Depreciation & amortization expense	40.03	30.02	74.65
Interest expense on borrowings	181.32	145.09	289.46
Interest income	(7.22)	(0.93)	(3.95)
Provision for Gratuity			-
Preliminary exp written off			0.08
Operating Profit before working capital changes	**1,746.84**	**558.70**	**1,820.96**
Changes in operating assets and liabilities:			
Increase/(decrease) in trade payables	124.05	287.52	(148.09)
Increase/(decrease) in other current liabilities	131.22	122.75	43.70
Increase/(decrease) in Short Term Borrowings	189.88	1,475.52	1,101.92
Increase/(decrease) in Short Term Provisions	0.10	0.56	0.61
Increase/(decrease) in Long Term Provisions	5.31	7.51	4.12
Decrease/(increase) in trade receivables	(1,660.94)	(1,405.72)	(412.15)
Decrease/(increase) in Inventory	(207.08)	(728.35)	(186.13)
Decrease/(increase) in Short Term loans and advances	(1,187.59)	(1,183.80)	(1,071.43)
Decrease/(increase) in Long Term loans and advances	-	(37.66)	340.89
Decrease/(increase) in other current assets	(85.85)	(221.97)	(175.18)
Decrease/(increase) in other Non-current assets	0.04	0.02	
	(2,690.85)	**(1,683.62)**	**(501.74)**
Cash generated from operations	(944.01)	(1,124.92)	1,319.22
Income taxes refunded/ (paid)	(309.13)		(41.70)
Net cash flow from operations (A)	**(1,253.13)**	**(1,124.92)**	**1,277.52**
Cash flow from investing activities			
Purchase of /Advances for property, plant & equipment and Intangible assets	(952.82)	(1,332.53)	(671.59)
Sale of property, plant & equipment			
Investment in Noncurrent Investment		(351.58)	(20.18)
(Increase)/Decrease in other advance			
Interest received	7.22	0.93	3.95
Purchase of Fixed Assets in acquisition of Business			(1,287.83)
Purchase of Investments in acquisition of Business			(331.40)
Purchase of Advances in acquisition of Business			(101.92)
Purchase of Trade Receivable in acquisition of Business			(1,248.27)
Purchase of Inventories in acquisition of Business			(710.15)
Purchase of Other Assets in acquisition of Business			(112.60)
Purchase of Trade advances in acquisition of Business			(378.55)
Purchase of Trade Payable in acquisition of Business			500.67
Purchase of Other Liabities in acquisition of Business			90.34
Purchase of Borrowings in acquisition of Business			2,401.29
Purchase of Deferred Tax in acquisition of Business			
Purchase of Provisions in acquisition of Business			5.70
Purchase of Cash & Cash Equivalents in acquisition of Business			34.76
Less: Cash & Cash Equivalents			(34.76)
Net cash used in investing activities (B)	**(945.60)**	**(1,683.18)**	**(1,860.53)**
Cash flow from financing activities			
Proceeds from issue of capital/equity shares		876.44	734.04
Further issue of capital	479.30		142.20
Proceeds from share premium	6,470.55	910.09	910.09
Share issue expenses	(1,083.72)	(115.17)	(127.19)
Proceeds/(Repayment) of Long Term Borrowings	116.64	1,320.65	(1,210.52)
Borrwing received against business acquisition			-
(Repayment)Receipt of borrowing			446.42
Interest paid	(181.32)	(145.09)	(289.46)
Net cash flow from/ (used in) financing activities (C)	**5,801.45**	**2,846.92**	**605.58**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	3,602.71	38.81	22.56
Cash and cash equivalents at the beginning of the year	25.56	3.00	3.00
Cash and cash equivalents at the closing of the year	**3,628.28**	**41.81**	**25.56**
Cash in hand	11.44	17.20	14.29
Balances with banks:			
- On current accounts	3,616.84	24.61	11.28
Total	**3,628.28**	**41.81**	**25.56**

FOR & ON BEHALF OF THE BOARD
ANONDITA MEDICARE LTD.

RESHANT GHOSH
Wholetime Director

ANONDITA MEDICARE LTD.

Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001
1960, First Floor, Outram Line, Delhi - 110009
Ph. : 011-23340155, 23342776 Mob:9810247478
E-mail : jainchopra.company@gmail.com

Independent Auditor's Limited Review Report on unaudited consolidated financial results of Anondita Medicare Limited for the half year ended September 30, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015

To,
The Board of Directors of Anondita Medicare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Anondita Medicare Limited** ("**the Holding Company**") its subsidiary and associate (the Holding Company its subsidiary and associate together referred to as "**the Group**") and its share of the net profit/(loss) after tax for the half year ended September 30, 2025 of its associate ("**the Statement**"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India.

   A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

   The Statement includes the results of the following entities:

M/s Anondita Healthcare and Rubber Products India Limited	Subsidiary
M/s Anondita Healthcare (Partnership Firm)	Associate

JAIN CHOPRA & COMPANY ★ NEW DELHI ★ CHARTERED ACCOUNTANTS

Jain Chopra & Company

Chartered Accountants

8, Chandra House, First Floor, Dr. Lane, Gole Market, New Delhi - 110001
1960, First Floor, Outram Line, Delhi - 110009
Ph. : 011-23340155, 23342776 Mob:9810247478
E-mail : jainchopra.company@gmail.com

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in AS 25 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The Statement includes the Group's share of net profit after tax of Rs. 147.98 139.80 lacs and Rs. 303.11 lacs for the half year ended September 30, 2025 and half year ended September 30, 2024 respectively as considered in the unaudited consolidated financial results, in respect of an subsidiary referred in para 4 above, whose interim financial statement has not been reviewed by us. This interim financial statement has been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

7. Our conclusion is not modified in respect of this matter.

For Jain Chopra & Company
Chartered Accountants
FR No. 002198N

Rajesh Kumar

Rajesh Kumar
Partner
M.No. 501860
UDIN: 25501860BMLYKV8880
Date: 13-11-2025
Place: New Delhi

JAIN CHOPRA & COMPANY CHARTERED ACCOUNTANTS NEW DELHI

ANONDITA MEDICARE LIMITED
(Formerly known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:U22193DL2024PLC428183

Consolidated Financial Statement as at September 30th, 2025

(Amount in Lakhs)

Particulars	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
I. EQUITY AND LIABLITIES			
1. Shareholders' funds			
(a) Share Capital	1,808.79	886.36	1,329.36
(b) Reservs and surplus	9,053.54	1,785.56	2,380.36
(c) Minority Interest	134.39	87.01	118.16
(d) Money received against share warrants			
2. Share application money pending allotment			
3. Non - current liabilities			
(a) Long-term borrowings	1,307.40	1,320.65	1,190.76
(b) Deferred Tax Liability (net)	24.06	17.30	8.56
(c) Other Long term liabilities			
(d) Long Term Provision	15.13	7.51	9.83
4. Current liabilities			
(a) Short-term borrowings	3,352.38	2,046.52	1,548.34
(b) Trade payables			
A) Total outstanding dues of micro enterprises and small enterprises	153.00	249.54	123.88
B) Total outstanding dues of creditors other than micro enterprises and small enterprises	484.05	73.11	257.65
(c) Other current liabilities	323.39	362.97	210.06
(d) Short-term Provisions	974.38	181.44	553.87
Total	17,630.52	7,017.96	7,730.83
ASSETS			
1) Non Current Assets			
(a) Property, Plant and Equipment and Intangible assets			
(i) Property, Plant and Equipment	1,277.25	1,246.61	1,237.04
(ii) Intangible assets			-
(a) Goodwill	19.18	19.18	19.18
(iii) Capital Work In Progress	1,522.08	50.36	649.61
(iv) Intangible assets under development			-
(b) Non-current Investments	331.40	331.40	331.40
(c) Deferred tax assets (net)	0.22	0.16	0.22
(d) Long-term loans and advances	37.66	37.66	37.66
(e) Other non - current assets	0.24	0.38	0.28
			-
2) Current Assets			-
(a) Current investments			-
(b) Inventories	1,450.10	951.05	1,349.86
(c) Trade receivables	4,809.67	1,907.55	2,675.33
(d) Cash and Bank balance	3,650.96	79.67	32.94
(e) Short-term loans and advances	3,706.27	2,122.85	973.96
(f) Other current assets	825.49	271.10	423.35
Total	17,630.52	7,017.96	7,730.83

For & On behalf of the Board
Anondita Medicare Limited

ANONDITA MEDICARE LTD.

Reshant Ghosh
Director

ANONDITA MEDICARE LIMITED

(Formerly Known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:U22193DL2024PLC428183

Consolidated Statement of Profit & Loss Account as at September, 2025

(Amount in Lakhs)

PARTICULARS	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
I. Revenue from operations	5,409.70	3,140.50	7,699.07
II. Other Income	40.77	10.26	13.88
III. Total Income (I +II)	**5,450.48**	**3,150.76**	7,712.95
IV. Expenses:			
Cost of Materials Consumed	2,353.22	1,482.69	3,376.69
Purchase of Stock-in-Trade	164.93	1.06	744.86
Change in inventories of finished goods, Work in progress and Stock in Trade	(79.18)	127.36	(293.20)
Employee benefit expense	348.10	261.85	686.80
Financial costs	182.35	145.32	291.09
Depreciation and amortization expense	40.87	36.27	75.79
Other expenses	702.49	295.04	618.70
Total Expenses	**3,712.78**	**2,350**	5,500.72
V. Profit before exceptional and extraordinary items and tax (III - IV)	**1,737.70**	801.17	2,212.22
VI. Exceptional Items			
VII. Profit before extraordinary items and tax (V - VI)	1,737.70	801.2	2,212.22
VIII. Extraordinary Items			
IX. Profit before tax (VII - VIII)	1,737.70	801.2	2,212.22
X. Tax expense:			
(1) Current tax	420.42	180.9	553.25
(2) Deferred tax Liability / (Assets)	15.49	17.3	8.50
XI. Profit(Loss) for the year from continuing operations (IX - X)	1,301.79	603.0	1,650.47
XII. Profit/(Loss) from discontinuing operations			
XIII. Tax expense of discounting operations			
XIV. Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)			
XV. Profit/(Loss) for the year (XI + XIV)	1,301.79	603.0	1,650.47
Profit for the Year attributable to			
a. Owners of the Company	1,285.56	569.7	1,588.21
b. Minority Interest	16.23	33.3	62.26
XVI. Earning per equity share:			
(1) Basic	9.12	6.16	14.11
(2) Diluted	9.12	6.16	14.11

For & on behalf of Board of Directors
Anondita Medicare Limited

ANONDITA MEDICARE LTD.

Reshant Ghosh
Wholetime Director

ANONDITA MEDICARE LIMITED

(Formerly Known as Anondita Healthcare)

Regd Address: Flat No.704, Narmada Block, N-6, Sector-D, Pocket-6, Vasant Kunj South West Delhi-110070
CIN:U22193DL2024PLC428183

Consolidated Statement of Cash Flow as at September 30, 2025

(Amount in Lakhs)

Particulars	For Half Year ended As at 30 September, 2025 (Unaudited)	For Half Year ended As at 30 September, 2024 (Unaudited)	Year Ended As at March 31, 2025 (Audited)
Profit before tax	1,730.47	784.33	2,212.22
Adjustments for:			
Depreciation & amortization expense	40.87	36.27	75.79
Interest expense on borrowings	247.33	163.82	320.74
Interest income	(7.22)	(0.93)	(3.95)
Loss on sale of Car		0.86	0.86
Provision for Gratuity		-	-
Preliminary exp written off		-	0.12
Operating Profit before working capital changes	**2,011.45**	**984.35**	**2,605.78**
Changes in operating assets and liabilities:			
Increase/(decrease) in trade payables	579.59	2.52	(484.82)
Increase/(decrease) in other current liabilities	113.33	126.15	(117.09)
Increase/(decrease) in Short Term Borrowing	1,105.14	1,776.61	-
Increase/(decrease) in Short Trem Provisions	0.10	(1.84)	0.61
Increase/(decrease) in Long Trem Provisions	5.31	7.51	4.12
Decrease/(increase) in trade receivables	(2,458.40)	(1,639.85)	(1,113.82)
Decrease/(increase) in Inventory	(92.09)	(587.70)	(276.37)
Decrease/(increase) in Short Term loans and advances	(2,033.41)	(2,008.34)	(1,456.43)
Decrease/(increase) in Long Term loans and advances	-	(37.66)	340.89
Decrease/(increase) in other current assets	(93.01)	(211.21)	(209.18)
Decrease/(increase) in other Non-current assets	0.04	0.02	
	(2,873.42)	**(2,573.80)**	**(3,312.09)**
Cash generated from operations	(861.97)	**(1,589.45)**	(706.31)
Income taxes refunded/ (paid)	(309.13)		(44.10)
Net cash flow from operations (A)	**(1,171.09)**	**(1,589.45)**	**(750.41)**
Cash flow from investing activities			
Purchase of /Advances for property, plant & equipment and Intangible ass	(953.55)	**(1,332.53)**	(673.90)
Sale of property, plant & equipment		**4.23**	4.23
Investment in Noncurrent Investment		**(351.58)**	(20.18)
(Increase)/Decrease in other advance		-	-
Interest received	7.22	**0.93**	3.95
			-
Purchase of Fixed Assets in acquisition of Business			(1,287.83)
Purchase of Investments in acquisition of Business			(331.40)
Purchase of Advances in acquisition of Business			(101.92)
Purchase of Trade Receivable in acquisition of Business			(1,248.27)
Purchase of Inventories in acquisition of Business			(710.15)
Purchase of Other Assets in acquisition of Business			(112.60)
Purchase of Trade advances in acquisition of Business			(378.55)
Purchase of Trade Payable in acquisition of Business			500.67
Purchase of Other Liabities in acquisition of Business			90.34
Purchase of Borrowings in acquisition of Business			2,401.29
Purchase of Deferred Tax in acquisition of Business			-
Purchase of Provisions in acquisition of Business			5.70
Purchase of Cash & Cash Equivalents in acquisition of Business			(26.72)
Less: Cash & Cash Equivalents			26.72
		-	
Net cash used in investing activities (B)	**(946.33)**	**(1,678.95)**	**(1,858.60)**
Cash flow from financing activities			
Proceeds from issue of capital/equity shares		**1,349.06**	734.16
Further Issue of Capital	479.30	-	142.20
Proceeds from Share Premium	6,470.55	**910.09**	1,464.36
Share Issue Expense	(1,083.72)	**(115.17)**	(192.11)
Proceeds/(Repayment) of Long Term Borrowings	116.64	**1,320.65**	(1,210.52)
Increase/(decrease) in Short Trem Borrowings		-	1,530.91
(Repayment)Receipt of borrowing		-	446.42
Interest paid	(247.33)	**(163.82)**	(320.74)
Net cash flow from/ (used in) financing activities (C)	**5,735.45**	**3,300.81**	**2,594.68**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	3,618.02	32.41	(14.33)
Cash and cash equivalents at the beginning of the year	32.94	**47.27**	47.27
Cash and cash equivalents at the closing of the year	**3,650.96**	**79.67**	**32.94**
Cash in hand	15.18	**21.64**	18.14
Balances with banks:			
- On current accounts	3,635.78	**58.03**	14.80
Total	**3,650.96**	**79.67**	**32.94**

For & On behalf of the board
Anondita Medicare Limited

RESHANT GHOSH
Wholetime Director

ANONDITA MEDICARE LTD.